Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Merck Sharp & Dohme LLC | 529 |
| 2 | Immunomedics Inc | 262 |
| 3 | Bayer Intellectual Property GmbH | 172 |
| 4 | Bristol Myers Squibb Co | 162 |
| 5 | Bayer Pharma AG | 150 |
| 6 | Genentech Inc | 137 |
| 7 | Centre National de la Recherche Scientifique | 133 |
| 8 | Vertex Pharmaceuticals Inc | 109 |
| 9 | Celgene Corp | 106 |
| 10 | Novartis AG | 103 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61P | Therapeutic activity (drug indications) | 16,955 |
| 2 | A61K | Medicinal preparations | 16,935 |
| 3 | C07D | Heterocyclic compounds | 5,588 |
| 4 | C07K | Peptides | 5,003 |
| 5 | C12N | Microorganisms, enzymes | 2,375 |
| 6 | G01N | Investigating / analysing materials | 1,690 |
| 7 | Y02A | Climate change adaptation | 1,430 |
| 8 | C07H | Sugars and derivatives | 1,028 |
| 9 | C12Q | Measuring/testing involving enzymes | 929 |
| 10 | C07F | Organometallic compounds | 798 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionMost-cited patents
Patents ranked by forward citations reveal the foundational inventions the field continues to build on.
| Title | Year | Assignee | Cited by |
|---|---|---|---|
| Polymer conjugates of ara-C and ara-C derivatives | 2002 | Enzon Pharmaceuticals Inc | 56 |
| ANTITUMOR COMBINATIONS CONTAINING ANTIBODIES RECOGNIZING SPECIFICALLY CD38 AND CYTARABINE | 2010 | Sanofi Aventis France | 49 |
| Preparing method for cytarabine | 2005 | ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. | 34 |
| VOLASERTIB ALONE OR IN COMBINATION WITH CYTARABINE FOR TREATING ACUTE MYELOID LEUKEMIA | 2012 | Boehringer Ingelheim International GmbH | 30 |
| Polymer conjugates of ara-C and ara-C derivatives | 2003 | エンゾン，インコーポレーテッド | 26 |
Where research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Acute Myeloid Leukemia Research | 158 |
| 2 | Acute Lymphoblastic Leukemia research | 51 |
| 3 | Lymphoma Diagnosis and Treatment | 34 |
| 4 | CNS Lymphoma Diagnosis and Treatment | 15 |
| 5 | Neutropenia and Cancer Infections | 15 |
| 6 | Chronic Myeloid Leukemia Treatments | 14 |
| 7 | Hematopoietic Stem Cell Transplantation | 14 |
| 8 | Retinoids in leukemia and cellular processes | 14 |
| 9 | Virus-based gene therapy research | 13 |
| 10 | Chronic Lymphocytic Leukemia Research | 12 |
Technology trend analysis
Cypris uses AI to connect emerging research themes to IP activity, commercialization signals, and underexplored opportunity areas.
See Cypris in actionWho's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Hagop M. Kantarjian | The University of Texas MD Anderson Cancer Center | 231 |
| 2 | Elihu H. Estey | The University of Texas MD Anderson Cancer Center | 132 |
| 3 | Jörge E. Cortes | The University of Texas MD Anderson Cancer Center | 122 |
| 4 | Wolfgang Hiddemann | Ludwig-Maximilians-Universität München | 79 |
| 5 | Farhad Ravandi | The University of Texas MD Anderson Cancer Center | 77 |
| 6 | Guillermo Garcia‐Manero | The University of Texas MD Anderson Cancer Center | 76 |
| 7 | Susan O’Brien | The University of Texas MD Anderson Cancer Center | 75 |
| 8 | Michael J. Keating | The University of Texas MD Anderson Cancer Center | 70 |
| 9 | Franco Mandelli | Sapienza University of Rome | 51 |
| 10 | Richard A. Larson | University of Chicago | 49 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia | 2003 | 3577 | Chronic Lymphocytic Leukemia Research |
| Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia | 2006 | 3493 | Chronic Lymphocytic Leukemia Research |
| Acute Myeloid Leukemia | 2015 | 3407 | Acute Myeloid Leukemia Research |
| Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation | 2017 | 2220 | Acute Myeloid Leukemia Research |
| Production of a tissue-like structure by contraction of collagen lattices by human fibroblasts of different proliferative potential in vitro. | 1979 | 2063 | Mesenchymal stem cell research |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the chemical composition and molecular structure of cytarabine?
Which organizations hold the most patents related to cytarabine?
What are the primary research areas involving cytarabine?
How extensive is the patent and publication coverage for cytarabine?
What key patent classifications are associated with cytarabine inventions?